Immunological Medicines for Cattles
Immunological veterinary medicinal products, including vaccines, are authorised for cattle.
Name
|
Description
|
Marketing Authorisation Holder
|
License Number
|
License Date
|
Animal
|
Further Information
|
Rispoval IBR-Marker vivum
|
BHV1-Infektion
|
Zoetis Deutschland GmbH
|
496a/93 |
28.10.1994 |
Rind |
PharmNet.Bund
|
Hiprabovis IBR Marker Live
|
BHV1-Infektion
|
Laboratorios Hipra S.A., Spanien
|
EU/2/10/114/001-002 |
27.01.2011 |
Rind |
EPAR: Hiprabovis IBR Marker Live
|
Rispoval IBR-Marker inactivatum
|
BHV1-Infektion
|
Zoetis Deutschland GmbH
|
497a/93 |
28.10.1994 |
Rind |
PharmNet.Bund
|
Bovilis IBR Marker live
|
BHV1-Infektion
|
Intervet Deutschland GmbH
|
PEI.V.11616.01.1 |
02.02.2012 |
Rind |
PharmNet.Bund
|
Bovilis IBR Marker inac
|
BHV1-Infektion
|
Intervet Deutschland GmbH
|
PEI.V.03246.01.1 |
23.09.2005 |
Rind |
PharmNet.Bund
|
Syvazul BTV 3
|
Blauzungenkrankheit, Serotyp 3
|
Laboratorios Syva S.A., Spanien
|
EU/2/24/332 |
20.02.2025 |
Schaf, Rind |
EPAR: Syvazul BTV 3
|
Bluevac-3
|
Blauzungenkrankheit, Serotyp 3
|
CZ Vaccines S.A.U., Spanien
|
EU/2/24/331 |
20.02.2025 |
Schaf, Rind |
EPAR: Bluevac-3
|
Bluevac-4
|
Blauzungenkrankheit, Serotyp 4
|
CZ Veterinaria S.A., Spanien
|
PEI.V.11839.01.1 |
25.05.2016 |
Schaf, Rind |
PharmNet.Bund
|
Bluevac BTV
|
Blauzungenkrankheit, Serotyp 8, 4 oder 1
|
CZ Veterinaria S.A., Spanien
|
EU/2/11/122/001-003 |
14.04.2011 |
Schaf, Rind |
EPAR: Bluevac BTV
|
Zulvac 1+8 Bovis
|
Blauzungenkrankheit, Serotypen 1 und 8
|
Zoetis Belgium S.A., Belgien
|
EU/2/12/139/001-003 |
08.03.2012 |
Rind |
EPAR: Zulvac 1+8 Bovis
|
BTVPUR
|
Blauzungenkrankheit, Serotypen 1, 2, 4 oder 8
|
Boehringer Ingelheim Vetmedica GmbH
|
EU/2/10/113/001-050 |
17.12.2010 |
Rind, Schaf |
EPAR: BTVPUR
|
Zulvac BTV
|
Blauzungenkrankheit, Serotypen 1, 4 oder 8
|
Zoetis Belgium S.A., Belgien
|
EU/2/17/207/001-009 |
25.04.2017 |
Rind, Schaf |
EPAR: Zulvac BTV Ovis
|
SYVAZUL BTV
|
Blauzungenkrankheit, Serotypen 1, 4 oder 8
|
Laboratorios Syva, S.A.U., Spanien
|
EU/2/18/231/001-012 |
09.01.2019 |
Schaf, Rind |
EPAR: Syvazul BTV
|
DIVENCE TETRA
|
Bovine Virusdiarrhoe, Bovine Parainfluenza, Bovines Respiratorisches Synzytialvirus
|
Laboratorios Hipra, S.A., Spanien
|
EU/2/24/310 |
10.05.2024 |
Rind |
EPAR: DIVENCE TETRA
|
DIVENCE PENTA
|
Bovine Virusdiarrhoe, Bovine Parainfluenza, Bovines Respiratorisches Synzytialvirus, Bovines Herpesvirus
|
Laboratorios Hipra, S.A., Spanien
|
EU/2/24/307 |
10.04.2024 |
Rind |
EPAR: DIVENCE PENTA
|
DIVENCE IBR Marker Live
|
Bovines Herpesvirus
|
Laboratorios Hipra, S.A., Spanien
|
EU/2/24/318 |
20.08.2024 |
Rind |
EPAR: DIVENCE IBR Marker Live
|
Rispoval RS
|
BRSV-Infektion
|
Zoetis Deutschland GmbH
|
116a/89 |
28.10.2005 |
Rind |
PharmNet.Bund
|
NASYM
|
BRSV-Infektion
|
Laboratorios Hipra S.A., Spanien
|
EU/2/19/241 |
29.07.2019 |
Rind |
|
Rispoval RS+PI3 IntraNasal
|
BRSV-Infektion,
Parainfluenza-3
|
Zoetis Deutschland GmbH
|
PEI.V.03416.01.1 |
15.08.2006 |
Rind |
PharmNet.Bund
|
Rispoval 3-BRSV-PI3-BVD
|
BRSV-Infektion,
Parainfluenza-3,
BVD/MD
|
Zoetis Deutschland GmbH
|
PEI.V.03128.01.1 |
21.04.2005 |
Rind |
PharmNet.Bund
|
Rispoval 2 / BRSV + Pi3
|
BRSV-Infektion, Bovine Parainfluenza
|
Zoetis Deutschland GmbH
|
PEI.V.12018.01.1 |
18.11.2020 |
Rind |
|
Bovilis IntraNasal RSP Live
|
BRSV-Infektion, Bovine Parainfluenza
|
Intervet Deutschland GmbH
|
PEI.V.11976.01.1 |
18.05.2019 |
Rind |
PharmNet.Bund
|
BOVALTO Respi Intranasal
|
BRSV-Infektion, Parainfluenza-3
|
Boehringer Ingelheim Vetmedica GmbH
|
PEI.V.11947.01.1 |
19.03.2018 |
Rind |
PharmNet.Bund
|
Mucosiffa
|
BVD/MD
|
Ceva Tiergesundheit GmbH
|
PEI.V.03518.01.1 |
06.03.2008 |
Rind |
PharmNet.Bund
|
Bovela
|
BVD/MD
|
Boehringer Ingelheim Vetmedica GmbH
|
EU/2/14/176/001-016 |
22.12.2014 |
Rind |
EPAR: Bovela
|
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 530 in BAnz AT 16.06.2025 B4.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.